中心效应与腹膜透析腹膜炎结局:全国登记分析
该回顾性队列研究基于ANZDATA登记,纳入2004-2014年澳大利亚所有发生腹膜炎的腹膜透析患者,共9,100次腹膜炎发作(4,428例患者,51个中心)。结果显示抗生素治愈率为69%,各中心间变异为38%-86%,中心特征(尤其是PD患者比例和经验性抗生素覆盖)显著影响腹膜炎结局。
要点
- 腹膜炎抗生素治愈率在中心间变异大(38%-86%),中心效应贡献显著
- PD患者比例>29%的中心治愈率更高,导管移除、转HD和复发风险更低
- 经验性抗生素覆盖革兰阳性及阴性菌的中心治愈率更高
核心结论
- 中心效应是澳大利亚PD中心间腹膜炎结局差异的重要贡献因素。
研究设计与样本
- 回顾性队列研究,使用ANZDATA登记数据,纳入2004-2014年澳大利亚所有发生腹膜炎的PD患者,共9,100次腹膜炎发作(4,428例患者,51个中心)。
主要发现
- 抗生素治愈率为69%(6,285/9,100次发作),各中心间范围为38%-86%。
- PD患者比例>29%的中心治愈 odds 更高(调整OR 1.21,95%CI 1.04-1.40),导管移除(OR 0.78,95%CI 0.62-0.97)、转HD(OR 0.78,95%CI 0.62-0.97)和复发(OR 0.68,95%CI 0.48-0.98) odds 更低。
- 经验性抗生素覆盖革兰阳性及阴性菌比例更高的中心治愈 odds 更高(OR 1.22,95%CI 1.06-1.42)。
- 患者层面与治愈 odds 更高相关的因素包括较年轻年龄和致病力较低的微生物(凝固酶阴性葡萄球菌、链球菌和培养阴性)。
- 调整患者特征后中心间治愈 odds 变异增加9%,调整中心特征后变异降低66%。
临床怎么用
- 中心应优化PD患者比例和经验性抗生素覆盖范围以改善腹膜炎治愈率。
局限性
- 回顾性研究设计,使用登记数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Peritonitis is a common cause of technique failure in peritoneal dialysis (PD). Dialysis center-level characteristics may influence PD peritonitis outcomes independent of patient-level characteristics. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Using Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) data, all incident Australian PD patients who had peritonitis from 2004 through 2014 were included. PREDICTORS: Patient- (including demographic data, causal organisms, and comorbid conditions) and center- (including center size, proportion of patients treated with PD, and summary measures related to type, cause, and outcome of peritonitis episodes) level predictors. OUTCOMES & MEASUREMENT: The primary outcome was cure of peritonitis with antibiotics. Secondary outcomes were peritonitis-related catheter removal, hemodialysis therapy transfer, peritonitis relapse/recurrence, hospitalization, and mortality. Outcomes were analyzed using multilevel mixed logistic regression. RESULTS: The study included 9,100 episodes of peritonitis among 4,428 patients across 51 centers. Cure with antibiotics was achieved in 6,285 (69%) peritonitis episodes and varied between 38% and 86% across centers. Centers with higher proportions of dialysis patients treated with PD (>29%) had significantly higher odds of peritonitis cure (adjusted OR, 1.21; 95% CI, 1.04-1.40) and lower odds of catheter removal (OR, 0.78; 95% CI, 0.62-0.97), hemodialysis therapy transfer (OR, 0.78; 95% CI, 0.62-0.97), and peritonitis relapse/recurrence (OR, 0.68; 95% CI, 0.48-0.98). Centers with higher proportions of peritonitis episodes receiving empirical antibiotics covering both Gram-positive and Gram-negative organisms had higher odds of cure with antibiotics (OR, 1.22; 95% CI, 1.06-1.42). Patient-level characteristics associated with higher odds of cure were younger age and less virulent causative organisms (coagulase-negative staphylococci, streptococci, and culture negative). The variation in odds of cure across centers was 9% higher after adjustment for patient-level characteristics, but 66% lower after adjustment for center-level characteristics. LIMITATIONS: Retrospective study design using registry data. CONCLUSIONS: These results suggest that center effects contribute substantially to the appreciable variation in PD peritonitis outcomes that exist across PD centers within Australia.
引用
- Htay H, Cho Y, Pascoe EM, et al. Center Effects and Peritoneal Dialysis Peritonitis Outcomes: Analysis of a National Registry. Am J Kidney Dis. 2017. PMID: 29289475. doi:10.1053/j.ajkd.2017.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。